Humanigen: Rises after filing emergency use application for COVID-19 treatment

Humanigen

28/05/2021 14:13

** Drug developer's shares  HGEN.O  up 5.1% at $23.9
premarket
    ** Co says it has submitted emergency use authorization
application to the U.S. FDA for its drug, lenzilumab, to treat
patients hospitalized with COVID-19  urn:newsml:reuters.com:*:nBwb8NqCsa
    ** In late-stage trial, lenzilumab improved chances of
survival without ventilation in newly hospitalized COVID-19
patients - HGEN 
    ** Up to Thursday's close, stock had risen ~30% this year

 (Reporting by Dania Nadeem in Bengaluru)
 ((Dania.Nadeem@thomsonreuters.com;))